Company Overview of Parion Sciences, Inc.
Parion Sciences, Inc. is engaged in the research, development, and commercialization of treatments to restore patient’s innate mucosal surface defenses. Its pipeline includes P-1037, a clinical stage ENaC blocker for pulmonary disease and cystic fibrosis; tPAD, a trans-nasal pulmonary aerosol delivery system for inhaled drug delivery for cystic fibrosis; mucolytic agents for respiratory diseases; Parion CFTR corrector program for cystic fibrosis; and P-321 for dry eye disease. The company was formerly known as CyFi, Inc. and changed its name to Parion Sciences, Inc. in October 2002. Parion Sciences, Inc. was founded in 1999 and is based in Durham, North Carolina.
2800 Meridian Parkway
Durham, NC 27713
Founded in 1999
Key Executives for Parion Sciences, Inc.
Parion Sciences, Inc. Key Developments
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
To contact Parion Sciences, Inc., please visit www.parion.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.